Four-Week Supplementation of Water-Soluble Tomato Extract Attenuates Platelet Function in Chinese Healthy Middle-Aged and Older Individuals: A Randomized, Double-Blinded, and Crossover Clinical Trial.

Background and Aims: Platelets are linked to atherosclerotic development and pathological thrombosis. Single dose of water-soluble tomato extract (WTE) which is a natural extraction can exert anti-platelet effects after 3 or 7 h in British healthy people. However, the effects of WTE supplementation on platelet function in Chinese healthy middle-aged and older individuals have not been studied, and the effects or safety of 4-week WTE supplementation also remain unclear. The present study aims to determine the effects of WTE on platelet function, and explore the safety of 4-week WTE supplementation in Chinese healthy middle-aged and older individuals.
Methods: A randomized, double-blinded, and crossover clinical trial was conducted. Firstly, 105 individuals were randomly divided into two groups that received WTE (150 mg/day) or placebo for 4 weeks. Then, after a washout period of 2 weeks, two groups exchanged groups and continued for another 4-week intervention. Platelet aggregation, P-selectin, activated GPIIbIIIa, plasma platelet factor 4 (PF4), β-thromboglobulin (β-TG), and thromboxane B2 (TXB2) were tested at baseline, 4, 6, and 10 weeks.
Results: Compared with the placebo group, 150 mg/day WTE supplement for 4 weeks significantly reduced ADP-induced or collagen-induced platelet aggregation (-10.8 ± 1.8 or -3.9 ± 1.5%, P < 0.05), ADP-induced or collagen-induced platelet P-selectin expression (-6.9 ± 1.5 or -6.6 ± 1.3%, P < 0.05), ADP-induced or collagen-induced activated GPIIbIIIa (-6.2 ± 2.0 or -3.8 ± 2.0%, P < 0.05). Besides, 4-week intervention of 150 mg WTE per day also resulted in significant reductions in plasma PF4 (-120.6 ± 33.2 ng/mL, P < 0.05) and β-TG (-129.7 ± 27.5 ng/mL, P < 0.05) and TXB2 (-42.0 ± 4.0 ng/mL, P < 0.05), while had no effects on coagulation function and liver or renal function. Interestingly, 2-week washout period is enough to reverse the inhibitory effect of 4-week WTE supplementation on platelet function.
Conclusion: WTE supplementation for 4 weeks could moderately reduce platelet activation, aggregation, and granule secretion in Chinese healthy middle-aged and older individuals, and these effects are safe. After 2-week washout period, the inhibitory effect of 4-week WTE on platelet function can be eliminated. Clinical Trial Registration: [http://www.chictr.org.cn/], identifier [ChiCTR-POR-17012927].

Introduction

Cardiovascular diseases (CVDs), the major non-communicable diseases, are the leading cause of deaths globally (1), especially accounting for more than 40% of deaths in China (2). Global Burden of Disease (GBD) study has shown that there were an approximated 93.8 million prevalent cases of CVDs overall during 2016 in China, more than twice that of 1990, thus resulting the serious burden of CVDs in China (3).

Pathological mechanisms of CVDs are mainly atherosclerosis (AS) and thrombosis (4). A large number of studies have shown that platelets play an important role in the initiation and progression of atherothrombosis as platelet activation, aggregation and the release of platelet granule contents participated in the formation of thrombus and atherosclerotic plaques (5). A previous study has shown that the progressive decline of platelet health was observed in the middle-aged and older individuals, marked by an increase in oxidative stress and platelet hyper-activation (6). Therefore, primary prevention of CVDs by antiplatelet strategy is of considerable importance in Chinese middle-aged and older individuals.

At present, various anti-platelet drugs (such as aspirin, clopidogrel, and ticagrelor) are widely used for prevention and treatment of CVDs such as atherosclerosis (7, 8). However, a large number of reports indicated that large-scale use of these drugs may increase bleeding risk or cause thrombocytopenia (9, 10). These side effects limit the application of anti-platelet drugs in the early prevention and treatment of thrombotic diseases. Therefore, other safe and effective anti-platelet strategies for early prevention should be developed to reduce the risks of CVDs in middle-aged and older individuals.

Epidemiological studies have found that there was a negative association between tomato consumption and the incidence of CVDs in Mediterranean countries (11, 12). However, some studies have shown that the relationship between lycopene rich in tomatoes and CVDs is not strong (11, 13), thus suggesting that other unidentified compounds in tomatoes may play a role in reducing the risk of CVDs. Further in vitro studies showed that water-soluble tomato extract (WTE) exerted inhibitory effect on ADP-induced platelet activation and ADP- or collagen-induced platelet aggregation (14). WTE is a natural mixture that is obtained from fresh tomatoes (Lycopersicon esculentum) by physically removing fat-soluble components in tomatoes, and mainly composed by adenosine, chlorogenic acid, and rutin (14). Previous acute clinical trials have shown that a single dose of WTE inhibited platelet aggregation and activation after 3 or 7 h in the British adults (14, 15). Recent reviews have shown that WTE was a potential therapeutic agent for inhibiting platelet function and might circumvent the negative drawbacks of using aspirin, clopidogrel, or ticagrelor (16, 17). However, the effect and safety of 4-week administration of WTE remains unclear, and there is no study exploring the effect of WTE on platelet function in Chinese middle-aged and older individuals. In view of differences in response of platelet to anti-platelet drugs among different races (18, 19), the lack of study in other races limits the popularization of WTE to a wider population in other countries.

To address these issues, our present study aimed to conduct a randomized placebo-controlled crossover trial to determine the effect and safety of 4-week administration of WTE on platelet function in Chinese middle-aged and older individuals.

Materials and Methods

Study Population

All the subjects were recruited from the medical examination center of the first affiliated hospital of Sun Yat-sen University and community health center through flyers, medical record reviews, or clinicians’ recommendations in Guangzhou, Guangdong, China. This study was approved by the Ethics Committee of Sun Yat-sen University (No. 2016036), and was conducted in strict accordance with the principles of the Declaration of Helsinki. This trial was registered at Chinese clinical trial registry as ChiCTR-POR-17012927. All participants signed written informed consent forms prior to enrollment.

The inclusion criteria were: (1) men or women aged 40–65 years; (2) without serious vascular or hematological diseases; and (3) normal laboratory tests for hematuria, liver and kidney function, blood glucose, and lipids. The exclusion criteria were: (1) with the history of hypertension, infectious disease, hemostatic disorders, diabetes mellitus, and CVDs; (2) agents use that could influence platelet function; (3) lactating or pregnant women; and (4) allergic to tomatoes and their ingredients.

Study Design

This was a randomized crossover-designed controlled trial. First, a total of 105 eligible subjects were stratified by gender and then randomly divided into two group 1 or group 2 by random numbers generated by SPSS v22.0 (SPSS Inc., Chicago, IL, United States). Referring to other previous randomized controlled trials which focused on the effects of 4-week supplementation for other nutritional supplements rich in phytochemical (20–23), we took 4 weeks as the duration of WTE supplementation in this study. Individuals in group 1 took one WTE tablet (150 mg/day) and individuals in group 2 take one placebo tablet daily for 4 weeks, followed by a 2-week washout period. Then, the two groups switched groups and continued to take WTE (150 mg/day) or placebo tablets for another 4 weeks (Figure 1). During the 10-week trial period, all subjects were instructed to maintain their usual diet and lifestyle, but to refrain from tomatoes and tomato products. The 24-h dietary recall data were recorded on 3 consecutive days, and International Physical Activity Questionnaire (IPAQ) scores were collected via face-to-face interviews at baseline and after intervention (24, 25).

FIGURE 1

Flow diagram of the study population.

A technician who did not participate in the experiments, data collection or analysis was responsible for randomization, and the management of the packaged supplements. Participants, investigators, and laboratory technicians were blinded to the treatment assignments.

Use PASS software (version 11.0, NCSS Inc.) to estimate the sample size required for the study based on the conventional assumption of a two-tailed α level of 0.05 and β level of 0.10. According to the previous study (15), the change rates of platelet aggregation in the intervention group and the control group were −9.7 and −3.1% after the intervention of WTE. Based on a two-tailed α level of 0.05 and β level of 0.10, 42 participants in each group were needed. Considering a 10% loss to follow-up rate, 47 subjects are needed in each group at least.

Study Supplements

Water-soluble tomato extract tablets and placebo tablets were provided by DSM (Netherlands) and By-health (China). The WTE tablets contain 150 mg WTE (Fruitflow) which comprises nucleosides, polyphenols, and flavonoids purified from fresh tomatoes (L. esculentum) by using solid-phase extraction, as described in previous study (14) (refer to Supplementary Table 1 for the ingredients of the WTE tablets). The placebo tablets contained only maltodextrin. The weight, appearance, taste, and packaging of WTE tablets and placebo tablets were same.

Anthropometric Analyses and Assessment of Biochemical Biomarkers

Body weight, height, waist circumference (WC), hip circumference (HC), heart rate (HR), and blood pressure (BP) were measured according to standard protocols, as previously described (24, 25).

Fasting blood samples were obtained at 8–9 a.m. from each subject’s antecubital vein with a 21-gauge needle at the beginning and at weeks 4, 6, and 10 of the trial. Whole human blood was collected into a Vacutainer tube containing 3.8% sodium citrate (1/9, v/v) via venipuncture. The blood sample was then centrifuged at 1,700 × g for 15 min at 4°C to obtain plasma, and the blood sample with sodium citrate was then centrifuged at 200 × g for 10 min at 22°C to obtain platelet-rich plasma (PRP) (26). PRP was immediately used to assay platelet aggregation and activation or other related parameters. Plasma samples were stored at −80°C until subsequent analyses.

Fasting blood samples were subjected to LDL-C, HDL-C, serum TG, serum TC, fasting blood glucose (FBG), urea, uric acid (UA), creatinine, alanine aminotransferase, total protein, albumin, and globulin. Lipid profile analyses were performed on the Cobas c311 automated assay analyzer (c311, Roche Diagnostics, Switzerland). Enzymatic methods were used to determine the concentrations of HDL-C, LDL-C, TC, and TG. Other biochemical analyses included FBG, urea, UA, creatinine, alanine aminotransferase, total protein, albumin, and globulin were measured using the Cobas c311 automated assay analyzer. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin clotting time (TT), and plasma fibrinogen (Fib) estimations were performed on a Sysmex5100 system (Siemens Healthineers, Malvern, PA, United States).

The platelet granule contents including platelet factor 4 (PF4), β-thromboglobulin (β-TG), and thromboxane B2 (TXB2) in plasma were tested using an enzyme linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions. The PF4 and β-TG in plasma were detected via the double antibody sandwich method of ELISA (Abcam, United Kingdom). TXB2 is the stable product of the non-enzymatic hydration of thromboxane A2 (TXA2), thus the production of TXA2 in vivo is typically monitored by measurement of TXB2 (27). Therefore, as previous studies (28–31), we chose the R&D’s TXB2 competitive ELISA kit (R&D Systems, United States) to detect TXB2 for reflecting the production of TXA2. The SPARK® multimode microplate reader (Tecan, Switzerland) was used to record ODs at 450 nm.

Detection of Platelet Surface CD62P and GPIIbIIIa Expression by Flow Cytometric Analysis

In the clinical trial, PRP (5 × 106 platelets/mL) were labeled with FITC-conjugated anti-human CD62P antibody or PAC-1 antibody for 20 min and followed the stimulation of ADP or collagen, samples were then fixed with 1% paraformaldehyde and analyzed using a CytoFLEX flow cytometer (Beckman Coulter, CA, United States), and data were analyzed with CytExpert 2.0 (Beckman Coulter, CA, United States), as previously described (32, 33).

Detection of Platelet Aggregation by Light Aggregometry

Briefly, 500 μL of fresh PRP from citrated blood was incubated in a transparent cuvette at 37°C for 5 min. Then the cuvette was transferred into the detection hole of Chronolog aggregometer (Chrono-Log Corp., PA, United States) and stimulated by 5 μmol/L ADP or 2 μg/mL collagen. At least 500 μL of PRP need to be used for platelet aggregation test at a time, which means that a lot of whole blood needs to be collected. This is not in line with the principles of ethics. In addition, previous acute studies in Britain have found that WTE significantly inhibited collagen- and ADP-induced platelet aggregation (14, 15). Therefore, we measured platelet aggregation stimulated by collagen and ADP. Platelet aggregation was evaluated on a Chronolog aggregometer in PRP (3.0 × 108 platelets/mL) at 37°C with a sample stir speed of 1,000 rpm, and the maximum-reversible platelet aggregation was monitored and recorded for at least 6 min, as previously described (33, 34).

Statistical Analysis

SPSS 22.0 software was used for statistical analysis. In the clinical study, the data are expressed as the mean ± standard error of the mean (SEM) unless otherwise stated. For categorical variables, analysis was performed using the chi-square test. The changes after 4-week WTE supplementation or placebo supplementation were calculated as values after 4-week intervention (at 4 or 10 weeks) deducted from the values at baseline (at 0 week or after 2-week washout period). For continuous variables, variables were checked for normal distribution and were assessed by Kruskal–Wallis test if they were not normally distributed. The comparability of the two groups at baseline were assessed by one-way analysis of variance (ANOVA).

The effects of treatments were evaluated using one-way ANOVA, comparisons of each index at baseline (at 0 week or after 2-week washout period) and after 4-week intervention (at 4 or 10 weeks) between two groups were conducted using the Student’s t-test for unpaired data. The mean changes of each index between two groups after 4-weeks intervention were compared using the Student’s t-test for unpaired data. To explore the reversibility of 4-week supplementation of WTE, one-way ANOVA were used to assess changes between two groups at baseline, 4, 6, and 10 weeks. Stratified analyses were performed with ANOVA to compare the changes of platelet function after 4-week treatment stratified by gender. Differences were considered statistically significant at P < 0.05.

Role of Funding Source

All funders of the present study (namely National Natural Science Foundation of China, Shenzhen Science, Technology, and Innovation Commission, By-health Research Foundation and Scientific Research Foundation of Chinese Nutrition Society) only provided financial support and did not participate in the design, data collection, data analysis, interpretation of the clinical trial, and the writing of this manuscript.

Results

Characteristics and Diet Monitoring

A total of 105 individuals completed the trial and were included in the analysis (Figure 1). The characteristics of 105 individuals are shown in Table 1. At baseline, 105 individuals were comparable in terms of age, sex, height, BMI, WC, HC, HR, SBP, DBP, lipid profile, and routine blood test (Table 1 and Supplementary Table 2). After intervention, there was no significant difference between two groups in terms mentioned above (Table 1 and Supplementary Table 2). In addition, there was no significant difference between two groups in daily physical activity status or the intake of energy, total protein, carbohydrates, lipids, dietary fiber, and vitamins at baseline and after intervention (Supplementary Table 3).

TABLE 1

Anthropometrics of all participants at baseline and after treatment.

	Group 1 (n = 54)		Group 2 (n = 51)
	Baseline	After intervention	Baseline	After intervention
Gender (M/F)	16/38		15/36
Age, years	54.0 ± 7.4		53.6 ± 9.7
Weight (kg)	63.5 ± 11.5	63.4 ± 11.3	63.6 ± 11.5	63.6 ± 11.5
Height (cm)	160.3 ± 7.8	160.4 ± 7.8	160.3 ± 7.8	160.3 ± 7.8
BMI (kg/m2)	24.6 ± 3.2	24.6 ± 3.2	24.6 ± 3.2	24.6 ± 3.3
WC (cm)	84.746 ± 11.5	85.8 ± 8.5	84.4 ± 11.2	85.6 ± 10.6
HC (cm)	96.4 ± 7.0	95.9 ± 7.2	96.11 ± 6.8	96.4 ± 6.9
SBP (mmHg)	118.2 ± 16.2	118.8 ± 14.6	116.9 ± 14.6	117.9 ± 15.0
DBP (mmHg)	78.1 ± 10.6	79.1 ± 10.6	77.2 ± 10.0	80.2 ± 19.5
HR (beats/min)	73.4 ± 9.0	72.6 ± 8.0	73.7 ± 8.4	73.3 ± 8.3
ALT (U/L)	20.8 ± 10.8	22.4 ± 13.8	22.3 ± 15.7	20.4 ± 12.9
Total protein (g/L)	74.4 ± 3.4	72.8 ± 3.6	74.0 ± 5.7	73.0 ± 3.9
Albumin (g/L)	46.0 ± 2.5	45.6 ± 2.6	45.9 ± 4.1	46.3 ± 2.6
Globulin (g/L)	28.3 ± 3.0	27.2 ± 3.6	28.3 ± 3.1	26.6 ± 4.1
A/G	1.6 ± 0.2	1.7 ± 0.3	1.7 ± 0.2	1.8 ± 0.6
Urea (mmol/L)	4.9 ± 1.1	5.1 ± 1.4	4.8 ± 1.3	4.8 ± 1.1
Creatinine (μmol/L)	74.1 ± 17.6	73.1 ± 17.8	74.4 ± 15.3	72.6 ± 15.6
UA (μmol/L)	359.2 ± 100.4	352.4 ± 91.6	385.5 ± 104.8	346.3 ± 79.1
TG (mmol/L)	1.6 ± 0.9	1.4 ± 0.8	1.8 ± 1.1	1.7 ± 1.2
TC (mmol/L)	5.1 ± 1.0	5.1 ± 1.1	5.2 ± 0.9	5.2 ± 0.9
HDL-c (mmol/L)	1.4 ± 0.6	1.3 ± 0.3	1.4 ± 0.4	1.4 ± 0.5
LDL-c (mmol/L)	3.3 ± 0.9	3.4 ± 1.0	3.4 ± 0.8	3.5 ± 0.8

The data are expressed as mean ± SEM. There were no significant differences for any variable between the two groups at the baseline or after intervention. M, male; F, female; BMI, body mass index; NC, neck circumference; WC, waist circumference; HC, hip circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; TC, total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; TG, total triglyceride; UA, uric acid; ALT, alanine aminotransferase; A/G, albumin/globulin.

Water-Soluble Tomato Extract Supplementation Inhibited Platelet Activation and Aggregation in Chinese Healthy Middle-Aged and Older Individuals

At baseline, there were no significant differences in platelet activation and aggregation between two groups. Subjects consumed 150 mg of WTE or placebo tablet daily for 4 weeks. After 4-week intervention, 150 mg/day of WTE significantly reduced the percentage of ADP- or collagen-induced activated GPIIbIIIa positive platelets, with baseline levels of 51.8 ± 1.4 or 21.3 ± 1.5% and post-intervention levels of 45.6 ± 1.8 or 17.5 ± 1.2%, respectively (P < 0.05, Table 2). Four weeks of 150 mg/day WTE also significantly decreased the percentage of ADP- or collagen-induced P-selectin positive platelets, with baseline values of 51.2 ± 1.0 or 32.3 ± 1.0% and post-intervention values of 44.3 ± 1.1 or 25.7 ± 0.9% (P < 0.05, Table 2). Similarly, 150 mg/day WTE resulted in significant reductions in platelet aggregation stimulated by ADP or collagen, with baseline values of 72.3 ± 1.4 and 81.1 ± 1.2% and post-intervention values of 61.5 ± 1.6 and 77.2 ± 0.9% after 4-week supplementation (P < 0.05, Table 2). After 4-week intervention, placebo did not significantly change platelet activation and aggregation in Chinese healthy middle-aged and older individuals (P > 0.05, Table 2). In addition, there were significant differences between 150 mg/day WTE group and the placebo group in terms of platelet activation and aggregation after 4-week intervention (P < 0.05, Table 2).

TABLE 2

Effects of WTE on platelet activation and aggregation in healthy middle-aged and older individuals.

	Placebo (n = 105)			WTE (n = 105)
	Baseline	After intervention	Mean changea	Baseline	After intervention	Mean changea	P-valuee
ADP-induced platelet aggregation (%)	71.6 ± 1.5	70.0 ± 1.8	−1.6 ± 2.1	72.3 ± 1.4	61.5 ± 1.6[b, c]	−10.8 ± 1.8d	<0.001
Collagen-induced platelet aggregation (%)	80.4 ± 0.9	81.9 ± 0.9	1.5 ± 1.1	81.1 ± 1.2	77.2 ± 0.9[b, c]	−3.9 ± 1.5d	0.004
ADP-induced platelet P-selectin (%)	48.5 ± 1.0	53.4 ± 1.3	4.8 ± 1.4	51.2 ± 1.0	44.3 ± 1.1[b, c]	−6.9 ± 1.5d	<0.001
Collagen-induced platelet P-selectin (%)	31.0 ± 0.9	30.2 ± 1.0	−0.8 ± 1.2	32.3 ± 1.0	25.7 ± 0.9[b, c]	−6.6 ± 1.3d	<0.001
ADP-induced activated platelet GPIIbIIIa (%)	50.1 ± 1.5	55.2 ± 1.8	5.1 ± 1.7	51.8 ± 1.4	45.6 ± 1.8[b, c]	−6.2 ± 2.0d	0.001
Collagen-induced activated platelet GPIIbIIIa (%)	21.7 ± 1.5	24.7 ± 1.2	3.0 ± 1.9	21.3 ± 1.5	17.5 ± 1.2[b, c]	−3.8 ± 2.0d	0.003

The data are expressed as mean ± SEM. At the baseline, there were no significant differences for any variable between the two groups. In the placebo group, there are no significant differences for any variable after the 4-weeks treatment.

The percentage of ADP-induced activated GPIIbIIIa positive platelets from baseline to 4 weeks significantly decreased in the 150 mg/day WTE (−6.2 ± 2.0%, P < 0.05, Table 2). The percentage of collagen-induced activated GPIIbIIIa positive platelets from baseline to 4 weeks also significantly decreased in the 150 mg/day WTE groups (−3.8 ± 2.0%, P < 0.05), compared with the placebo group (3.0 ± 1.9%, Table 2). Similarly, the change in ADP- or collagen-induced platelet aggregation from baseline to 4 weeks in the 150 mg/day WTE group (−10.8 ± 1.8 or −3.9 ± 1.5%) was significantly different from the change in the placebo group (−1.6 ± 2.1 or 1.5 ± 1.1%, P < 0.05) (Table 2). Besides, there were significant differences between 150 mg/day WTE group (−6.9 ± 1.5 or −6.6 ± 1.3%) and the placebo group (4.8 ± 1.4 or −0.8 ± 1.2%) in the percentage of ADP- or collagen-induced P-selectin positive platelets (P < 0.05, Table 2). Stratified analyses indicated that WTE could significantly inhibit platelet activation and aggregation in whether male or female, and WTE might have more robust inhibition on platelet activation and aggregation among females (Supplementary Tables 4, 5).

Water-Soluble Tomato Extract Supplementation Reduced the Level of Platelet Granule Secretion in Chinese Healthy Middle-Aged and Older Individuals

One hundred and five individuals were comparable between two groups in terms of platelet granule secretion at baseline (P > 0.05, Table 3). Compared with baseline values, the 4 weeks of placebo supplementation did not significantly alter any of the variables (P > 0.05, Table 3). However, a 4-week intervention of 150 mg WTE per day can significantly reduce plasma β-TG from baseline value of 495.8 ± 19.1 ng/mL to post-intervention value of 366.1 ± 19.2 ng/mL (P < 0.05, Table 3). Four weeks of WTE at 150 mg/day also significantly decreased plasma PF4, with baseline value of 397.3 ± 24.5 ng/mL and post-intervention value of 276.7 ± 27.1 ng/mL (P < 0.05, Table 3). Similarly, 150 mg/day WTE resulted in significant reductions in TXB2, with baseline value of 160.5 ± 4.5 ng/mL and post-intervention value of 118.5 ± 6.8 ng/mL after 4-week supplementation (P < 0.05, Table 3).

TABLE 3

Effects of WTE on platelet granule secretion in healthy middle-aged and older individuals.

	Placebo (n = 105)			WTE (n = 105)
	Baseline	After intervention	Mean changea	Baseline	After intervention	Mean changea	P-valuee
β-TG (ng/mL)	519.4 ± 17.9	456.9 ± 17.9	−62.4 ± 24.6	495.8 ± 19.1	366.1 ± 19.2[b, c]	−129.7 ± 27.5	<0.001
PF4 (ng/mL)	393.0 ± 29.6	430.0 ± 27.4	37.0 ± 40.3	397.3 ± 24.5	276.7 ± 27.1[b, c]	−120.6 ± 33.2d	<0.001
TXB2 (ng/mL)	165.8 ± 4.0	164.8 ± 4.6	−1.0 ± 2.4	160.5 ± 4.5	118.5 ± 6.8[b, c]	−42.0 ± 4.0d	<0.001

The data are expressed as mean ± SEM. At the baseline, there were no significant differences for any variable between the two groups. In the placebo group, there are no significant differences for any variable after the 4-weeks treatment.

After 4-week intervention, there were significant differences between 150 mg/day WTE group and the placebo group plasma β-TG, PF4 and TXB2 (P < 0.05, Table 3). The plasma β-TG from baseline to 4 weeks significantly decreased (−129.7 ± 27.5 ng/mL) in the 150 mg/day WTE group (Table 3). The decrease in plasma PF4 from baseline to 4 weeks in the 150 mg/day WTE group (−120.6 ± 33.2 ng/mL) was significantly different from the change in the placebo group (37.0 ± 40.3 ng/mL, P < 0.05), as shown in Table 3. In addition, compared with the placebo group (−1.0 ± 2.4 ng/mL), the level of plasma TXB2 from baseline to 4 weeks was significantly reduced in the 150 mg/day WTE group (−42.0 ± 4.0 ng/mL, P < 0.05), as shown in Table 3. Stratified analyses indicated that WTE could significantly inhibit platelet granule secretion in whether male or female, and WTE might have more robust inhibition on platelet granule secretion among females (Supplementary Tables 4, 5).

The Inhibitory Effect of Water-Soluble Tomato Extract on Platelet Function Can Be Eliminated After 2-Week Washout Period

After 4-week intervention, 150 mg/day WTE can significantly reduce platelet activation, aggregation, and granule contents, compared with placebo (P < 0.05, Tables 2, 3). To evaluate the reversibility of anti-platelet effect of WTE, we further performed a 2-week washout period for all volunteers after 4-week intervention. Interestingly, after a 2-week washout period, there was no significant difference in the percentage of ADP- or collagen-induced activated GPIIbIIIa positive platelets, the percentage of ADP- or collagen-induced P-selectin positive platelets, platelet aggregation stimulated by ADP or collagen, plasma β-TG and TXB2 between 150 mg/day WTE group and placebo group (P > 0.05, Supplementary Tables 6, 7). These results showed that effects of 4-week WTE supplement on platelet activation, aggregation, and granule contents are reversible.

Safety Evaluation

Considering the anti-platelet ability of WTE, we carefully determined whether the clotting pathways were affected by WTE alongside anti-platelet effects. We therefore examined the coagulation function of subjects and found that 4-week intervention of WTE had no any adverse effects on PT, PT-INR, PT-R, APTT, TT, and Fib in Chinese healthy middle-aged and older individuals (P > 0.05, Table 4). Similarly, there was also no significant difference between two groups in urea, UA, creatinine, alanine aminotransferase, total protein, albumin, and globulin at baseline and after intervention, and these results suggested that 4-week intervention of WTE had no significant effect on liver and kidney function in Chinese healthy middle-aged and older individuals (P > 0.05, Table 1). In addition, no adverse events were reported during the intervention period.

TABLE 4

Effects of WTE on coagulation function in healthy middle-aged and older individuals.

	Placebo (n = 105)		WTE (n = 105)
	Baseline	After intervention	Baseline	After intervention
PT (s)	12.0 ± 0.6	11.0 ± 0.8	10.8 ± 0.8	10.9 ± 0.7
PT-INR	0.9 ± 0.07	0.9 ± 0.07	0.9 ± 0.07	0.9 ± 0.06
PT-R	0.9 ± 0.06	0.9 ± 0.06	0.9 ± 0.06	0.9 ± 0.06
APTT (s)	30.0 ± 3.7	29.3 ± 4.0	29.7 ± 3.8	29.3 ± 3.6
TT (s)	18.6 ± 1.2	18.2 ± 1.3	18.4 ± 1.2	18.2 ± 1.2
Fib (g/L)	2.8 ± 0.6	2.9 ± 0.6	2.8 ± 0.6	2.8 ± 0.6

The data are expressed as mean ± SEM. At the baseline, there were no significant differences for any variable between the two groups. There are no significant differences for any variable between two groups after the 4-weeks intervention. PT, prothrombin time; PT-INR, prothrombin time-international normalized ratio; PT-R, prothrombin time-ratio; APTT, activated partial thromboplasting time; TT, thrombin time; Fib, fibrinogen.

Discussion

In the present study, we set out to investigate the effects of WTE on platelet function in Chinese healthy middle-aged and older adults. For this purpose, we sought to perform a crossover comparison of 150 mg WTE and placebo, in Chinese healthy middle-aged and older adults fitting the target population for WTE consumers. The results have shown that supplementation of WTE can reduce plasma PF4, β-TG, TXA2, and inhibited agonist-induced platelet activation and aggregation in Chinese healthy middle-aged and older adults, and the effects of 4-week WTE supplementation on platelet activation, aggregation, and granule contents are reversible after the 2-week washout period.

Platelets can be activated first and then aggregate after the stimulation of ADP and Collagen (37). PF4 and β-TG are platelet-specific granule contents, which are lower in the platelet resting state, and can multiply when platelets are stimulated, and therefore can be widely used as indicators reflecting the release state of platelet granule secretion (38). Controlling platelet hyperactivity has become one of the important strategies to prevent the development of atherothrombosis and CVDs. Our previous experiments have indicated that WTE directly inhibited platelet activation, aggregation and thrombosis by using gel-filtered platelets and FeCl3-induced mesenteric artery thrombosis model (39). We conducted a randomized controlled crossover clinical trial to explore whether WTE can also reduce platelet activation and aggregation, and its effect on platelet granule secretion. WTE is now authorized by the European Food Safety Authority for daily consumption with 150 mg in the format of powder, tablet, or capsule (35). Therefore, we used the doses of 150 mg/day for our clinical trial. Our present studies proved that WTE supplementation significantly inhibited ADP- or collagen-induced platelet aggregation, platelet surface P-selectin expression, GPIIbIIIa activation, and TXA2 generation in Chinese healthy middle-aged and older individuals. Meanwhile, WTE supplementation can significantly reduce the level of platelet granule secretion including plasma PF4 and β-TG. These are consistent with previous studies in European (15, 36), suggesting that the anti-platelet properties of WTE is applicable not only to European healthy individuals, but also to Chinese healthy middle-aged and older individuals.

Clinical trials focused on nutrients have shown that the duration of nutrient supplementation is an important factor affecting its improvement effect (24, 25, 40–43). Previous studies explore that WTE supplementation exerts anti-platelet effects after 3 or 7 h, which is relatively short (15, 36). Niamh O’Kennedy etc., has found that WTE resulted in significant reductions about −4.5% in platelet aggregation stimulated by ADP after 7 h (36). Another study found that single dose of WTE could further reduce ADP-induced platelet aggregation (−11.7 ± 5.3%) combined with 7-day treatment of 75 mg aspirin (15). Our present study suggested that WTE can significantly reduce ADP-induced platelet aggregation (−10.8 ± 3.5%) after 4-week intervention, and this inhibitory effect of 4-week WTE intervention is better than the acute treatment of WTE and is similar to 7-day treatment of 75 mg aspirin combined with WTE. Besides, our study found that WTE significantly reduced collagen- or ADP-induced platelet activation and granule contents after 4-week intervention. These evidences indicated that daily intake of WTE for 4-week intervention might stably reduce platelet activation, aggregation, and granule contents in Chinese healthy middle-aged and older individuals.

Many anti-platelet drugs irreversibly inhibit platelet function and affect the life span of circulating platelets, which cause extra bleeding risks (9, 44). For instance, aspirin recognized as an irreversible inhibitor of cyclo-oxygenase is commonly used as oral anti-platelet drugs (45). Meta-analysis of 13 trials with 164,225 participants has found that the use of aspirin was not only associated with a lower risk of cardiovascular events, but also with an increased risk of major bleeding due to its irreversible inhibit on platelet (10, 45). Previous trials have proved that 150 mg of WTE for 7 h or 7 days did not affect prothrombin time and TT (15, 46). Considering that WTE possessed significant anti-platelet ability, we also carefully determined whether the clotting pathways are affected by WTE alongside anti-platelet effects in Chinese healthy middle-aged and older individuals. In our clinical trial, WTE exerts anti-platelet ability with no any adverse effects on the coagulation function related to prothrombin system after 4-week supplementation. Our previous animal experiment also found that WTE had no effect on the bleeding time of mice (39). This is consistent with our present study. Interestingly, our present study also found that the inhibitory effect of 4-week WTE on platelet function in Chinese healthy middle-aged and older individuals can be eliminated after 2-week washout period. The results indicated that the inhibitory effect of WTE on platelets was not similar with anti-platelet drugs and could be reversed after a washout period. In addition, we found that 4-week intervention of WTE had no effect on liver function and kidney function in Chinese healthy middle-aged and older individuals. This evidence indicated that daily intake of WTE is safe in Chinese healthy middle-aged and older individuals, and it has the potential to be applied for primary prevention of CVDs.

Recent in vitro study (47) quantitatively analyzes the effect of WTE on the inhibition of agonist-induced platelets with the involvement of several signaling molecules proteomics, and found that compared WTE-treated agonist-induced platelets with only agonist-induced platelets, 60 proteins were upregulated and 10 proteins were downregulated. Further validation indicated that WTE might also exert antiplatelet properties via decreasing Akt, glycogen synthase kinase 3β, p38 mitogen-activated protein kinase (MAPK), and heat shock protein (Hsp27) phosphorylation (47). Our previous in vitro experiments have also indicated that the inhibition of WTE on platelet activation and aggregation might be partly due to regulating the signaling pathway of PI3K/Akt and MAPKs (39). These results suggested that tomato might play an anti-platelet role via variety of signal pathways.

High performance liquid chromatography (HPLC) results revealed that WTE contains three main active ingredients, namely, nucleoside derivatives, phenolic conjugates, and flavonoid derivatives; the most representative among the three components are adenosine, chlorogenic acid, and rutin, respectively (35). These three substances can be used to quantify and evaluate the quality of WTE and ensure that WTE is as close to fresh tomatoes as possible. In general, nucleoside, polyphenols, and flavonoid provided platelet protection and improved platelet activation, adhesion and aggregation (48–50). Hence, the inhibitory effects of WTE on platelet granule secretion may be attributed to these three components, and we will further clarify the component which plays most important role on antiplatelet effects by non-targeted metabonomics in further research.

Strengths and Limitations

There are some strengths and limitations in our present study. The double-blind, randomized, placebo-controlled, and crossover trial design is the major strength of this study. Different from the previous trials only focused on the effects of single-dose WTE supplementation after 3 or 7 h in Britain, our present crossover trial up to 4-week WTE supplementation can be more conducive to guiding the application of WTE in Chinese. Another strength is that we tested platelet activation and aggregation at baseline and during follow-up, which are required to be detected within two hours right after blood collection, to determine the effect and reversibility of WTE on platelet in Chinese healthy middle-aged and older individuals. To monitor their dietary habits and physical activity, we maintained their usual dietary intake and physical activities via 24-h dietary recall data on 3 consecutive days and an IPAQ during the trial. It may be another strength of our study. Meanwhile, some limitations also existed in the study. The findings of our study which focused on Chinese healthy middle-aged and older individuals just indicate a potential benefit for primary prevention of CVDs in Chinese healthy middle-aged and older individuals, and the primary or secondary prevention of WTE on individuals with metabolic diseases merits further clinical study. As in most other randomized controlled trials using the maximum-reversible platelet aggregation as main outcome (51–53), our present study only focused on the effect of WTE on the maximum-reversible platelet aggregation, without evaluating its effect on the maximum irreversible aggregation rate. This may be another limitation of our study.

Conclusion

In summary, 150 mg WTE per day for 4-week supplementation can significantly inhibit platelet activation, aggregation, and granule secretion in Chinese healthy middle-aged and older individuals, and the effect of 4-week WTE is safe. After 2-week washout period, the inhibitory effect of 4-week WTE supplementation on platelet function can be eliminated. This study provides novel evidence to support the importance of WTE as a protective food supplementary for early prevention of CVDs in Chinese healthy middle-aged and older individuals.

Data Availability Statement

Due to the principles of ethics and data privacy security, the datasets presented in this article are not readily available. After publication, deidentified participant data, described in the manuscript, study protocol, statistical analysis plan, and informed consent form will be made available upon reasonable request via email to the corresponding author.

Ethics Statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Sun Yat-sen University (No. 2016036). The patients/participants provided their written informed consent to participate in this study.

Author Contributions

YY designed the trial. ZT, DF, KL, DZ, YL, QJ, XG, XM, YZ, and YM conducted all trial steps. ZT, DF, and KL conducted laboratory analyses. ZT and DF performed statistical analysis and drafted the manuscript. YY and HM revised and edited the draft manuscript. All authors read and approved the final manuscript.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.